Patents Assigned to Cambridge Enterprise Limited
  • Patent number: 10908318
    Abstract: We describe a luminescent device (120, 130) comprising a substrate (102) and a film comprising perovskite crystals (122, 132) deposited on the substrate, wherein the film comprising perovskite crystals is encapsulated with a layer (124, 134)) or within a matrix (124, 134) of an insulating oxide or an insulating nitride.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: February 2, 2021
    Assignees: CAMBRIDGE ENTERPRISE LIMITED, KING ABDULAZIZ CITY FOR SCIENCE & TECHNOLOGY
    Inventors: Richard Henry Friend, Guangru Li, Dawei Di, Reza Saberi Moghaddam, Zhi Kuang Tan
  • Patent number: 10906814
    Abstract: A method for producing nanoplates derived from a layered material, includes the steps: (a) mixing particles of said layered material with a carrier liquid to form a dispersion of said particles in said carrier liquid; (b) pressurizing the dispersion to a pressure of at least 10 kpsi; and (c) forcing the dispersion along a microfluidic channel under said pressure, to apply a shear rate of at least 105 s?1 to said particles in the dispersion. Exfoliation of nanoplates from said particles is thereby caused. The nanoplates may be graphene nanoplates, for example. Steps (b) and (c) may be repeated for a number of cycles in order to promote exfoliation. The method may be carried out using a microfluidizer.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: February 2, 2021
    Assignee: CAMBRIDGE ENTERPRISE LIMITED
    Inventors: Panagiotis Karagiannidis, Stephen Anthony Hodge, Andrea Carlo Ferrari, Felice Torrisi
  • Patent number: 10894948
    Abstract: The invention provides methods and materials for resetting or sustaining a human stem cell in a “naïve” or “ground” state, based on the use of media including combinations of inhibitors. An example naïve culture medium comprises a PKC inhibitor, a MEK inhibitor. Also provided are methods of obtaining or propagating such cells, cells obtained using these methods, and novel culture media, which can be used in these methods.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: January 19, 2021
    Assignee: CAMBRIDGE ENTERPRISE LIMITED
    Inventors: Austin Smith, Ge Guo, Yasuhiro Takashima
  • Publication number: 20210010022
    Abstract: The invention relates to a nucleic acid construct for bi-allelic conditional modification of a target gene and methods of use thereof.
    Type: Application
    Filed: May 26, 2017
    Publication date: January 14, 2021
    Applicants: Cambridge Enterprise Limited, Genome Research Limited
    Inventors: William SKARNES, Bonkyoung KOO, Juergen FINK, Jihoon KIM, Alessandra MERENDA, Camelia Roxana MICSIK, Amanda Maria Hei-Ran ANDERSSON-ROLF
  • Patent number: 10887566
    Abstract: An image display system is provided and includes: at least one first projection unit, configured to project rays of N images on a first plane, so that the rays of the N images are projected on N first regions of the first plane, where the N images are images of a target object photographed based on N angles, and N?2; and at least one first refraction unit, configured on the first plane, and configured to perform refraction processing on the rays of the images projected on the first regions, so that the rays of the N images are collected on a common display region. In this way, presentation of a three-dimensional image can adapt to a human eye viewing habit.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: January 5, 2021
    Assignees: Huawei Technologies Co., Ltd., Cambridge Enterprise Limited
    Inventors: Jia Jia, Jhensi Chen, Daping Chu, Jun Yao
  • Publication number: 20200390385
    Abstract: This invention relates to the methods for the identification and isolation of cancer stem cells from cultured cancer cell lines. Cell line-derived cancer stem cells isolated using the present methods may be useful, for example, in assays to screen compounds for anti-cancer stem cell activity and in target discovery methods for identifying novel expressed genes and druggable targets. The invention also relates to the screening of compounds for activity against cell line-derived cancer stem cells.
    Type: Application
    Filed: November 25, 2019
    Publication date: December 17, 2020
    Applicant: Cambridge Enterprise Limited
    Inventor: Toru Kondo
  • Patent number: 10865488
    Abstract: A method of producing graphene sheets comprising the steps of, (a) forming a carbonaceous powder by electrochemical erosion of a graphite electrode in a molten salt comprising hydrogen ions, (b) recovering the resulting carbonaceous powder from the molten salt liquid, and (c) thermally treating the carbonaceous powder by heating the carbonaceous powder in a non-oxidising atmosphere to produce a thermally treated powder comprising graphene sheets.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: December 15, 2020
    Assignee: Cambridge Enterprise Limited
    Inventors: Derek Fray, Ali Kamali
  • Patent number: 10856057
    Abstract: Methods and devices for manipulating optical signals. In one example, a LCOS (liquid crystal on silicon) device includes a surface bearing an anti-reflection structure. The anti-reflection structure includes i) a physical surface having a topography with features having lateral dimensions of less than 2000 nm and having an average refraction index which decreases with distance away from the surface; and ii) a configuration of the topography, averaged over lateral dimensions of greater than 2000 nm, varies with lateral position on the surface.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: December 1, 2020
    Assignee: Cambridge Enterprise Limited
    Inventors: Daping Chu, Brian Robertson
  • Publication number: 20200357487
    Abstract: The present invention provides a method of determining the disease status in a subject, the method comprising: a) obtaining sequence data for the T-cell and/or B-cell receptor repertoire in a sample obtained from a subject; b) determining a data set of overlapping k-mer frequencies in the sequence data obtained in a); c) reducing data dimensionality of the data set of k-mer frequencies determined in b) to generate a reduced data set of k-mer frequencies; d) classifying the sample according to disease status based on the reduced data set determined in c) by performing any suitable form of statistical analysis, including, but not limited to, cluster analysis, on the reduced data set; and e) optionally applying the approach described in a) to d) to classify samples of unknown disease status on the basis of their similarity to samples of known disease status.
    Type: Application
    Filed: November 5, 2018
    Publication date: November 12, 2020
    Applicant: CAMBRIDGE ENTERPRISE LIMITED
    Inventors: Elizabeth SOILLEUX, Anna AUER-FOWLER
  • Patent number: 10826414
    Abstract: An apparatus is provided for harvesting energy from mechanical vibrations with an improved power output. The apparatus comprises a frame (22), a first member (20) comprising a piezoelectric material, a cantilever beam (26) and an electrode. The first member is fixed to the frame at a first position and a second position and extends between the first and second positions. The cantilever beam has a first end fixed to the first member between the first position and the second position and a second end fixed to a proof mass (24). The electrode is fixed to the first member at a position between the first position and the second position. In another aspect, the apparatus may comprise a plurality of proof masses connected to the first member between the first and second positions in a spaced relationship to one another.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: November 3, 2020
    Assignee: Cambridge Enterprise Limited
    Inventors: Yu Jia, Ashwin Arunkumar Seshia, Sijun Du
  • Publication number: 20200298236
    Abstract: A fluidic device is provided. The fluidic device comprises a separation channel having at its upstream end a junction, a first channel for supplying a first fluid flow, a second channel for supplying a second fluid flow. The first and second channels meet at the junction are adapted to provide the first fluid flow in the separation channel sheathed by the second fluid flow, such that the first fluid flow does not contact the separation channel walls. The separation channel, the first and second channels are provided as a unitary piece, or where the separation channel and the first and second channels are provided as a non-unitary piece comprising a plurality of parts, the parts are of the same material.
    Type: Application
    Filed: December 11, 2018
    Publication date: September 24, 2020
    Applicants: Cambridge Enterprise Limited, Fluidic Analytics Limited
    Inventors: Tuomas Pertti Jonathan Knowles, Kadi Liis Saar, Tadas Kartanas, Thomas Mueller
  • Patent number: 10761392
    Abstract: We describe a multimode reconfigurable optical spatial mode multiplexing system having first and second first and second input beams and a beam combiner to combine these into an optical output. At least one of the paths comprises a polarisation-independent reconfigurable phase modulator to impose a controllable phase profile on an input beam in an input beam phase modulating optical path, to controllably convert a spatial mode order of the input beam from a lower to a higher order spatial mode. The system also has a control input to control the phase modulator to configure the phase profile for the mode conversion. The input beams are combined into a multiple spatial mode combined beam output independent of a polarisation of the input beams. The number of spatial modes of the combined beam can be more than a number of spatial modes in either of the first and second input beams separately.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: September 1, 2020
    Assignee: Cambridge Enterprise Limited
    Inventors: Daping Chu, Haining Yang
  • Publication number: 20200254455
    Abstract: A microfluidic device (11) is provided for separation and analysis of microfluidic samples. The device comprises: a separation channel (10); a first electrolyte channel (12) configured to provide a flow of high conductivity electrolyte solution, in use; and provided with a positive electrode (13) at a downstream outlet of the channel; a second electrolyte channel (14) configured to provide a flow of high conductivity electrolyte solution, in use, and provided with a negative electrode (15) at a downstream outlet of the channel; and wherein the flow of electrolyte through the first and second electrolyte channels removes electrophoresis products and gas bubbles from the device; and wherein the presence of the electrolyte provides a substantially homogenous electric field across the separation channel.
    Type: Application
    Filed: February 17, 2017
    Publication date: August 13, 2020
    Applicants: Cambridge Enterprise Limited, Fluidic Analytics Limited
    Inventors: Yingbo Zhang, Thomas Mueller, Tuomas Pertti Jonathan Knowles
  • Patent number: 10739355
    Abstract: The invention relates to biomarkers and methods of diagnosing or monitoring bipolar disorder, or a predisposition thereto.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: August 11, 2020
    Assignee: Cambridge Enterprise Limited
    Inventors: Sabine Bahn, Jason Cooper, Frieder Haenisch
  • Patent number: 10730862
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: August 4, 2020
    Assignees: Yale University, Glaxosmithkline Intellectual Property Development, Cambridge Enterprise Limited University of Cambridge
    Inventors: Craig M. Crews, Dennis Buckley, Alessio Ciulli, William Jorgensen, Peter C. Gareiss, Inge Van Molle, Jeffrey Gustafson, Hyun-Seop Tae, Julien Michel, Denton Wade Hoyer, Anke G. Roth, John David Harling, Ian Edward David Smith, Afjal Hussain Miah, Sebastien Andre Campos, Joelle Le
  • Publication number: 20200224001
    Abstract: The present invention concerns a material, based on fibrillar, elongated, or disk-like colloidal particles, that has a high scattering efficiency, a method that is suitable for preparing such a material, and the use of such a material. The material can be used as, or as a part of, a pigment, paint or protective coating in various industries, but due to its high scattering, and due to the fact that the material appears white even as a thin membrane, it is an interesting option also in the paper and pulp, cosmetic and medical industries.
    Type: Application
    Filed: September 26, 2018
    Publication date: July 16, 2020
    Applicants: AALTO KORKEAKOULUSÄÄTIÖ SR, Cambridge Enterprise Limited
    Inventors: Matti Toivonen, Olli Ikkala, Silvia Vignolini, Olimpia Domitilla Onelli
  • Patent number: 10700295
    Abstract: The present invention provides complexes of the formula (L)M(X), in which M is a metal atom selected from copper, silver and gold; L is a carbene ligand; and X is a monoanionic ligand. The complexes are useful as light emitters in the emissive zone of light-emitting devices such as OLEDs. The present invention also provides organometallic complexes which exhibit RASI photoemission, and the use of the same in light-emitting devices such as OLEDs.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: June 30, 2020
    Assignees: UEA ENTERPRISES LIMITED, CAMBRIDGE ENTERPRISE LIMITED
    Inventors: Manfred Bochmann, Alexander Sergeyevich Romanov, Daniel John Nicholas Credgington, Dawei Di, Le Yang
  • Patent number: 10700238
    Abstract: A quantum-confined device (100) and method for manufacture thereof. The device (100) comprises a substrate (10) having at least one protrusion (12) and a layer of a two-dimensional material (14) arranged thereupon. The layer of the two-dimensional material (14) is arranged on the substrate (10) and the at least one protrusion (12), the at least one protrusion (12) causing localised strain in the layer of the two-dimensional material (14) to form a quantum dot or a quantum wire at the region of localised strain.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: June 30, 2020
    Assignee: Cambridge Enterprise Limited
    Inventors: Mete Atature, Dhiren Kara, Carmen Palacios Berraquero
  • Patent number: 10690656
    Abstract: The present application relates to materials and methods for exploiting synthetic lethality and/or chemo-sensitisation in DNA damage response (DDR) pathways. In particular, the application relates to ubiquitin hydrolase protein Ubiquitin Specific Protease 4 (USP4) and its association with DDR pathways. Further, the use of USP4 inhibitors in the treatment of cancer and methods of screening is described, in particular, use of inhibitors of USP4 in the treatment of tumours defective in double-strand break repair (DSBR) and/or tumours resistant to platinum-based chemotherapy, or to sensitise, i.e. chemosensitise or radiosensitise tumours to other therapeutic agents.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: June 23, 2020
    Assignees: MISSION THERAPEUTICS LIMITED, CAMBRIDGE ENTERPRISE LIMITED
    Inventors: Xavier Jacq, Helen Robinson, Yaara Ofir-Rosenfeld, Stephen Jackson, Paul Wijnhoven, Ryotaro Nishi
  • Publication number: 20200191799
    Abstract: The invention provides methods of diagnosing and treating multiple sclerosis (MS) patients, including methods of identifying and treating multiple sclerosis patients who are at increased risk of developing a secondary autoimmune disease following lymphocyte depletion, caused, e.g., by treatment with an anti-CD52 antibody. Also embraced are methods of selecting treatment regimens for MS patients, and reagents useful in the above methods.
    Type: Application
    Filed: February 25, 2020
    Publication date: June 18, 2020
    Applicant: Cambridge Enterprise Limited
    Inventors: Alasdair J. Coles, Joanne L. Jones, Alastair Compston